Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Opko Blames Rayaldee Snub On Manufacturer

This article was originally published in Scrip

Executive Summary

Opko Health Inc. on March 30 disclosed it had received a complete response letter (CRL) from the FDA on the firm's secondary hyperparathyroidism (SHPT) drug Rayaldee (calcifediol) – blaming the snub on deficiencies with the company's third-party manufacturer, Catalent Pharma.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register